ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
October 04, 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), executed an exclusive licensing agreement on September 30, 2021,...
ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
September 01, 2021 12:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101...
PULMOHEAL™/ ARTIVEDA™ IS CLINICALLY ACTIVE AGAINST MILD AND MODERATE COVID-19.
August 24, 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and COVID-19,...
ONCOTELIC AND GOLDEN MOUNTAIN PARTNERS FORMING A JOINT VENTURE FOR IPO
August 16, 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and COVID-19...
ONCOTELIC CLOSES COVID-19 CLINICAL TRIAL EARLY.
June 15, 2021 09:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, California, June 15, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic" or the “Company”), a leading developer of TGF-β therapeutics for oncology,...
Oncotelic Joins Chopra Foundation and Heart Foundation of India to Provide Relief for India's Explosive 2nd Wave of Covid.
May 04, 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, California, May 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic"), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.
April 20, 2021 12:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and...
ONCOTELIC THERAPEUTICS, INC. ANNOUNCED SYNERGY BETWEEN OT-101 AND IL-2 (PROLEUKIN) AT AACR-2021
April 19, 2021 12:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC) announced today a presentation at AACR-2021 (American Association...
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES PRESENTATION AT AYURVEDIC PERSPECTIVES ON COVID-19.
March 31, 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra...
ONCOTELIC THERAPEUTICS, INC. (FORMERLY MATEON THERAPEUTICS, INC.) NAME AND SYMBOL CHANGE.
March 30, 2021 09:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Financial...